Englander Institute for Precision Medicine

Publications

Found 692 results
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
D
De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli P et al..  2019.  Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab.. Clin Cancer Res. 25(13):3839-3846.
De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J et al..  2022.  Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? Future Oncol. 18(35):3867-3874.
De Martino M, Vanpouille-Box C, Galluzzi L.  2021.  Immunological barriers to immunotherapy in primary and metastatic breast cancer.. EMBO Mol Med. 13(8):e14393.
De Martino M, Rathmell JC, Galluzzi L, Vanpouille-Box C.  2024.  Cancer cell metabolism and antitumour immunity.. Nat Rev Immunol.
De Micheli AJ, Laurilliard EJ, Heinke CL, Ravichandran H, Fraczek P, Soueid-Baumgarten S, De Vlaminck I, Elemento O, Cosgrove BD.  2020.  Single-Cell Analysis of the Muscle Stem Cell Hierarchy Identifies Heterotypic Communication Signals Involved in Skeletal Muscle Regeneration.. Cell Rep. 30(10):3583-3595.e5.
De Micheli AJ, Spector JA, Elemento O, Cosgrove BD.  2020.  A reference single-cell transcriptomic atlas of human skeletal muscle tissue reveals bifurcated muscle stem cell populations.. Skelet Muscle. 10(1):19.
de Wit R, Powles T, Castellano D, Necchi A, Lee J-L, van der Heijden MS, Matsubara N, Bamias A, Fléchon A, Sternberg CN et al..  2022.  Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.. Br J Clin Pharmacol. 88(7):3182-3192.
de Wit R, Wülfing C, Castellano D, Kramer G, Eymard J-C, Sternberg CN, Fizazi K, Tombal B, Bamias A, Carles J et al..  2021.  Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.. ESMO Open. 6(5):100241.
de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard J-C, Bamias A, Carles J et al..  2019.  Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.. N Engl J Med. 381(26):2506-2518.
Desai P, Mencia-Trinchant N, Savenkov O, Simon MS, Cheang G, Lee S, Samuel M, Ritchie EK, Guzman ML, Ballman KV et al..  2018.  Somatic mutations precede acute myeloid leukemia years before diagnosis.. Nat Med. 24(7):1015-1023.
Deshpande AS, Ulahannan N, Pendleton M, Dai X, Ly L, Behr JM, Schwenk S, Liao W, Augello MA, Tyer C et al..  2022.  Identifying synergistic high-order 3D chromatin conformations from genome-scale nanopore concatemer sequencing.. Nat Biotechnol. 40(10):1488-1499.
Dewhurst SM, Yao X, Rosiene J, Tian H, Behr J, Bosco N, Takai KK, de Lange T, Imielinski M.  2021.  Structural variant evolution after telomere crisis.. Nat Commun. 12(1):2093.
Dhaouadi N, Vitto VAngela Mar, Pinton P, Galluzzi L, Marchi S.  2023.  Ca signaling and cell death.. Cell Calcium. 113:102759.
Dhingra P, Fu Y, Gerstein M, Khurana E.  2017.  Using FunSeq2 for Coding and Non-Coding Variant Annotation and Prioritization.. Curr Protoc Bioinformatics. 57:15.11.1-15.11.17.
Dhingra P, Martinez-Fundichely A, Berger A, Huang FW, Forbes ANeil, Liu EMinwei, Liu D, Sboner A, Tamayo P, Rickman DS et al..  2017.  Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network.. Genome Biol. 18(1):141.
Dhital B, Santasusagna S, Kirthika P, Xu M, Li P, Carceles-Cordon M, Soni RK, Li Z, Hendrickson RC, Schiewer MJ et al..  2023.  Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer.. Cell Rep Med. 4(2):100937.
Dixon G, Pan H, Yang D, Rosen BP, Jashari T, Verma N, Pulecio J, Caspi I, Lee K, Stransky S et al..  2021.  QSER1 protects DNA methylation valleys from de novo methylation.. Science. 372(6538)
Do KTrinh, Rasp DJN-P, Kastenmüller G, Suhre K, Krumsiek J.  2019.  MoDentify: phenotype-driven module identification in metabolomics networks at different resolutions.. Bioinformatics. 35(3):532-534.
Do KTrinh, Wahl S, Raffler J, Molnos S, Laimighofer M, Adamski J, Suhre K, Strauch K, Peters A, Gieger C et al..  2018.  Characterization of missing values in untargeted MS-based metabolomics data and evaluation of missing data handling strategies.. Metabolomics. 14(10):128.
Doane AS, Elemento O.  2022.  Alterations in transcriptional networks in cancer: the role of noncoding somatic driver mutations.. Curr Opin Genet Dev. 75:101919.
Doane AS, Chu C-S, Di Giammartino DCampigli, Rivas MA, Hellmuth JC, Jiang Y, Yusufova N, Alonso A, Roeder RG, Apostolou E et al..  2021.  OCT2 pre-positioning facilitates cell fate transition and chromatin architecture changes in humoral immunity.. Nat Immunol. 22(10):1327-1340.
Dooley BJ, Verma A, Ding R, Yang H, Muthukumar T, Lubetzky M, Shankaranarayanan D, Elemento O, Suthanthiran M.  2020.  Urinary Cell Transcriptome Profiling and Identification of ITM2A, SLAMF6, and IKZF3 as Biomarkers of Acute Rejection in Human Kidney Allografts.. Transplant Direct. 6(8):e588.
Drozdz MM, Doane AS, Alkallas R, Desman G, Bareja R, Reilly M, Bang J, Yusupova M, You J, Eraslan Z et al..  2022.  A nuclear cAMP microdomain suppresses tumor growth by Hippo pathway inactivation.. Cell Rep. 40(13):111412.
Duan X, Zhang T, Feng L, de Silva N, Greenspun B, Wang X, Moyer J, M Martin L, Chandwani R, Elemento O et al..  2024.  A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.. Cell Stem Cell. 31(1):71-88.e8.
Dutta A, Panja S, Virk RK, Kim JYeji, Zott R, Cremers S, Golombos DM, Liu D, Mosquera JMiguel, Mostaghel EA et al..  2017.  Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.. Eur Urol. 72(4):499-506.